5 Dividend Stocks to Buy According to Billionaire Ken Fisher

In this article, we will discuss the 5 dividend stocks to buy according to billionaire Ken Fisher. If you want to explore some of Ken Fisher’s top dividend stock picks, you can go to 12 Dividend Stocks to Buy According to Billionaire Ken Fisher.

5. Merck & Co., Inc. (NYSE:MRK)

Fisher Asset Management’s Stake Value: $1,351,347,000

Percentage of Fisher Asset Management’s 13F Portfolio: 0.91%

Dividend Yield as of February 6: 2.73%

On January 24, Merck & Co., Inc. (NYSE:MRK) declared a quarterly cash dividend of $0.73 per common share. The dividend is payable on April 10 to shareholders of record at the close of business on March 15. As of February 6, Merck & Co., Inc. (NYSE:MRK) is offering a forward dividend yield of 2.73% and has gained 17.56% over the past six months.

This February, Truist analyst Robyn Karnauskas raised his price target on Merck & Co., Inc. (NYSE:MRK) to $118 from $106 and reiterated a Buy rating on the shares.

At the end of Q4 2022, Fisher Asset Management held a stake worth $1.35 billion in Merck & Co., Inc. (NYSE:MRK). The investment covers 0.91% of Ken Fisher’s 13F portfolio and the stock is one of Fisher’s top dividend stocks to buy now.

Here is what Baron Funds had to say about Merck & Co., Inc. (NYSE:MRK) in its Q4 2022 investor letter:

“Merck & Co., Inc. (NYSE:MRK) is a large-cap pharmaceutical company with a deep heritage in drug discovery. Share gains were led by the continued growth of key asset Keytruda, the leading immune oncology agent used to treat a variety of cancers. Shares also benefited from increased investor interest as Merck proves its ability to scale its Gardasil vaccine that had previously been constrained by supply issues. We retain long-term conviction, as we expect Keytruda to solidify its position as the best-selling biopharmaceutical drug of all time.”